Comparison of Side Effects and Tolerability Between Intravesical Bacillus Calmette-Guerin, Reduced-Dose BCG and Gemcitabine for Non-Muscle Invasive Bladder Cancer
Joshua M. Kuperus, Ross D. Busman, Susan K. Kuipers, Helen T. Broekhuizen, Sabrina L. Noyes, Christopher M. Brede, Conrad M. Tobert, Brian R. Lane
Topics & Concepts
MedicineTolerabilityGemcitabineBladder cancerInternal medicineUrologyCancerAdverse effectBladder and Urothelial Cancer TreatmentsImmune responses and vaccinationsUrinary and Genital Oncology Studies